TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3469225

Group type: EXPERIMENTAL
Intervention: Thick plain wire bonded only to the canines
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Thick twisted wire bonded only to the canines
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Thin twisted wire bonded to each tooth
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Removable retainers
Number of subjects: 44

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 44
Study: 30655097

Group type: EXPERIMENTAL
Intervention: Experimenter watching
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Experimenter left the room
Number of subjects: 86

Group type: COMPARATOR
Intervention: Experimenter turned away
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Novel boxes
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Familiar boxes
Number of subjects: 86
Study: 27502287

Group type: EXPERIMENTAL
Intervention: DCV-TRIO for 12 weeks
Number of subjects: 217

Group type: COMPARATOR
Intervention: DUAL for 24 weeks
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: DCV-TRIO
Number of subjects: 217

Group type: COMPARATOR
Intervention: DUAL
Number of subjects: 217
Study: 26255087

Group type: EXPERIMENTAL
Intervention: Natural (n = 80)
Number of subjects: 159

Group type: COMPARATOR
Intervention: HRT (n = 79)
Number of subjects: 159
Study: 23088552

Group type: EXPERIMENTAL
Intervention: Alcohol-free chlorhexidine (CHX; Paroex)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Essential oils (EO; Listerine)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 20
Study: 21700944

Group type: EXPERIMENTAL
Intervention: Plasmin
Number of subjects: 15

Group type: COMPARATOR
Intervention: rtPA
Number of subjects: 15
Study: 19433378

Group type: EXPERIMENTAL
Intervention: Community-based informational campaign
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of the campaign and a cognitive-behavioral small group intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison group (participants from a second college campus)
Number of subjects: 0
Study: 16426317

Group type: EXPERIMENTAL
Intervention: Alemtuzumab induction
Number of subjects: 88

Group type: COMPARATOR
Intervention: Antithymocyte globulin induction
Number of subjects: 88
Study: 14983952

Group type: EXPERIMENTAL
Intervention: Screening with transrectal ultrasonography (TRUS) and sextant prostate biopsy when PSA >4 ng/mL (or >2.9 ng/mL after May 1998)
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: Early recall attendance after initial screening
Number of subjects: 4278

Group type: EXPERIMENTAL
Intervention: Second screening round
Number of subjects: 4278

Group type: COMPARATOR
Intervention: Control group (no diagnostic tests)
Number of subjects: 4278

Group type: COMPARATOR
Intervention: Overall mortality
Number of subjects: 4278
Study: 10919682

Group type: EXPERIMENTAL
Intervention: Salbutamol 200 microg four times daily via HFA 134a pMDI (Ventolin CFC-free)
Number of subjects: 547

Group type: COMPARATOR
Intervention: Salbutamol 200 microg four times daily via CFC pMDI (Ventolin)
Number of subjects: 547
Study: 8639796

Group type: EXPERIMENTAL
Intervention: Working Formulation (WF) - intermediate/high-grade
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Working Formulation (WF) - low-grade
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: MCL
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Follicle center cell lymphomas
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Diffuse large B-cell lymphomas
Number of subjects: 670
Study: 1601560

Group type: EXPERIMENTAL
Intervention: 20-meter shuttle run test (20-MST)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: University of Montreal track test (UM-TT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Laboratory treadmill test
Number of subjects: 11
Study: 2864847

Group type: EXPERIMENTAL
Intervention: Esmolol
Number of subjects: 110

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 110
Study: 30673755

Group type: COMPARATOR
Intervention: Peri-urban residents
Number of subjects: 671

Group type: COMPARATOR
Intervention: Rural Highland residents
Number of subjects: 671
Study: 29345992

Group type: EXPERIMENTAL
Intervention: Patient navigation-enhanced case management for 12 months
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Substance use disorder treatment in jail
Number of subjects: 270

Group type: COMPARATOR
Intervention: Latino individuals
Number of subjects: 270
Study: 27650051

Group type: EXPERIMENTAL
Intervention: Intramuscular betamethasone (11.4 mg Celestone Chronodose), repeated weekly if risk of very preterm birth remained
Number of subjects: 963

Group type: COMPARATOR
Intervention: Saline placebo, repeated weekly if risk of very preterm birth remained
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Intramuscular betamethasone (11.4 mg Celestone Chronodose)
Number of subjects: 963

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 963
Study: 25024623

Group type: EXPERIMENTAL
Intervention: BM‐MNCs transplantation plus routine medical treatment
Number of subjects: 47

Group type: COMPARATOR
Intervention: Medical treatment only (Control)
Number of subjects: 47
Study: 22351510

Group type: EXPERIMENTAL
Intervention: Positive response-outcome contingencies (Experiment 1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Some outcomes not contingent on participants' responses (Experiment 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative response-outcome contingency with manipulated performance expectancies (Experiment 3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Generalized ratings to novel stimuli through derived relations (all experiments)
Number of subjects: 0
Study: 20552089

Group type: EXPERIMENTAL
Intervention: Acrylic resin specimens
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Denture liner specimens
Number of subjects: 21
Study: 18347544

Group type: EXPERIMENTAL
Intervention: SRL/MMF
Number of subjects: 51

Group type: COMPARATOR
Intervention: TAC/MMF
Number of subjects: 51
Study: 16094217

Group type: EXPERIMENTAL
Intervention: MMRV (1 dose)
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: MMRV (2 doses)
Number of subjects: 480

Group type: COMPARATOR
Intervention: M‐M‐RII and VARIVAX (1 dose)
Number of subjects: 480
Study: 12477671

Group type: EXPERIMENTAL
Intervention: 12.5 mg dolasetron i.v.
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: 20 mg metoclopramide i.v.
Number of subjects: 387

Group type: COMPARATOR
Intervention: Saline as placebo i.v.
Number of subjects: 387
Study: 10652047

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (0.5 mg/kg) administered at the time of transplantation and again one month later
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 9037847

Group type: EXPERIMENTAL
Intervention: Nisoldipine (10 mg daily)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 1370735

Group type: EXPERIMENTAL
Intervention: Continuous aprotinin infusion (0.1‐0.4 Mill. KIU/hr)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bolus aprotinin (0.5 Mill. KIU on three occasions)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Continuous aprotinin infusion
Number of subjects: 23

Group type: COMPARATOR
Intervention: Bolus aprotinin
Number of subjects: 23
Study: 6380717

Group type: EXPERIMENTAL
Intervention: Combined treatment of radiotherapy and local external hyperthermia
Number of subjects: 77

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Immediate combination of heat and large radiation fractions
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Interval of 4 hr between heat and radiation
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Highest hyperthermic treatment and largest radiation fractions
Number of subjects: 77
Study: 30026282

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia for 24 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Mild therapeutic hypothermia
Number of subjects: 40
Study: 29241357

Group type: EXPERIMENTAL
Intervention: CBD (1000 mg/day)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study: 26355193

Group type: EXPERIMENTAL
Intervention: Interactive emotion training with musical engagement
Number of subjects: 15

Group type: COMPARATOR
Intervention: Interactive emotion training without musical engagement
Number of subjects: 15
Study: 24667140

Group type: EXPERIMENTAL
Intervention: 60% normoxic VO(2)peak performed in a normoxic environment (NI-NE)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 60% hypoxic VO(2)peak performed in a normoxic environment (HI-NE)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 60% hypoxic VO(2)peak performed in a hypoxic environment (HI-HE)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 11
Study: 23015193

Group type: EXPERIMENTAL
Intervention: tPA (alteplase)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 21123471

Group type: EXPERIMENTAL
Intervention: Traditional swaddling
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Nonswaddling
Number of subjects: 1279
Study: 17651058

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (above median diet score)
Number of subjects: 3042

Group type: COMPARATOR
Intervention: Unhealthy diet adherence (below median diet score)
Number of subjects: 3042
Study: 15951518

Group type: EXPERIMENTAL
Intervention: Web-based personalized feedback
Number of subjects: 0
Study: 11113795

Group type: EXPERIMENTAL
Intervention: Fiberotomy performed on 11 patients 1 week before debonding
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (12 patients)
Number of subjects: 23
Study: 9028551

Group type: EXPERIMENTAL
Intervention: Intravenous CMV hyperimmune globulin (0.4 g/kg on day -8, 0.2 g/kg on days -1, +7, +14, +21, +28, +35, +42, +56, +70)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 28
Study: 8301064

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 3492974

Group type: EXPERIMENTAL
Intervention: Lidocaine (2 mg/kg)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 91
Study: 2639785

Group type: EXPERIMENTAL
Intervention: 2% dibasic sodium citrate in poloxamer 407 (test dentifrice)
Number of subjects: 175

Group type: COMPARATOR
Intervention: 0.76% sodium monofluorophosphate (control dentifrice)
Number of subjects: 175
Study: 31755634

Group type: EXPERIMENTAL
Intervention: Screening and treatment for HCV
Number of subjects: 12246

Group type: EXPERIMENTAL
Intervention: Screening programs
Number of subjects: 12246

Group type: EXPERIMENTAL
Intervention: Awareness of serological status
Number of subjects: 12246
Study: 31301054

Group type: EXPERIMENTAL
Intervention: CoQun® (ophthalmic solution of Coenzyme Q10 and Vitamin E)
Number of subjects: 612

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 612
Study: 28489775

Group type: EXPERIMENTAL
Intervention: Nimodipine 7.5 μg/(kg × h) injected 30 minutes before anesthesia induction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline (control group)
Number of subjects: 60
Study: 26003225

Group type: EXPERIMENTAL
Intervention: Cathodal direct current stimulation (rctDCS) with 2mA intensity and 20 min duration applied to the visual cortex, 5 consecutive sessions 1-5 days prior to menstruation.
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham stimulation (placebo control).
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cathodal direct current stimulation (rctDCS).
Number of subjects: 20
Study: 24002506

Group type: EXPERIMENTAL
Intervention: Distress Thermometer and Problem List (DT&PL)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 220
Study: 21565138

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with Kangliu Zengxiao Decoction (KLZX)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with KLZX
Number of subjects: 74
Study: 19223200

Group type: EXPERIMENTAL
Intervention: P-adiponectin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: P-leptin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: U-adiponectin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: U-leptin
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Albuminuria
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: GFR
Number of subjects: 52
Study: 16980837

Group type: EXPERIMENTAL
Intervention: Energy conservation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 0
Study: 15117407

Group type: EXPERIMENTAL
Intervention: HRT after downregulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HRT in menopause
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HST in the natural cycle
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Down regulation plus HRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural cycle plus HRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Menopause plus HRT
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Natural cycle
Number of subjects: 0
Study: 11014951

Group type: EXPERIMENTAL
Intervention: Intramuscular progesterone (200 mg/day)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intravenous albumin (100 ml of 20%)
Number of subjects: 96
Study: 9241103

Group type: EXPERIMENTAL
Intervention: Vitamin C 1 g day(‐1) for 4 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no supplementation)
Number of subjects: 20
Study: 8355939

Group type: EXPERIMENTAL
Intervention: Polybutester skin suture
Number of subjects: 50

Group type: COMPARATOR
Intervention: Nylon skin suture
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both suture materials
Number of subjects: 50
Study: 3721630

Group type: EXPERIMENTAL
Intervention: Beta‐adrenergic blockade
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (no beta-blockade)
Number of subjects: 12
Study: 30352317

Group type: EXPERIMENTAL
Intervention: Intervention to increase physical activity and improve diet
Number of subjects: 953

Group type: EXPERIMENTAL
Intervention: Baseline response efficacy
Number of subjects: 953
Study: 26987489

Group type: EXPERIMENTAL
Intervention: Clinician Judgment
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Death or Disability Estimates
Number of subjects: 111
Study: 24956496

Group type: EXPERIMENTAL
Intervention: Triple therapy (telaprevir, ribavirin, pegylated-interferon alfa)
Number of subjects: 136

Group type: COMPARATOR
Intervention: Dual therapy (boceprevir, ribavirin, pegylated-interferon alfa)
Number of subjects: 136
Study: 22079391

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Q10) supplementation at a dose of 90 mg daily for 8 weeks
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (Q10) supplementation
Number of subjects: 23
Study: 19517167

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 220
Study: 18386567

Group type: EXPERIMENTAL
Intervention: Rhubarb combined with enteral nutrition (10% rhubarb liquid medication, 100 mL before operation, 50 mL at 18th and 42th hour post-operation)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Enteral nutrition via nasal feeding (starting from the 42nd hour to the 8th day after operation)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional fluid supplement and parenteral nutrition
Number of subjects: 56
Study: 15723737

Group type: EXPERIMENTAL
Intervention: Acute pancreatitis (AP) patients
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Colorectal cancer (CA) patients
Number of subjects: 52

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 52
Study: 12537464

Group type: EXPERIMENTAL
Intervention: Moderate beer consumption (330 mL of beer/day for 30 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Mineral water (control group)
Number of subjects: 48
Study: 11022808

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 176

Group type: COMPARATOR
Intervention: No alcohol consumption
Number of subjects: 176
Study: 9068514

Group type: EXPERIMENTAL
Intervention: Intraaortic Balloon Pump (IABP) for 48 hours
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no IABP)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patients with recurrent ischemia
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no recurrent ischemia)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Patients with adverse clinical events (death, stroke, reinfarction, emergency revascularization)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (no adverse clinical events)
Number of subjects: 102
Study: 8340155

Group type: EXPERIMENTAL
Intervention: Ridogrel (300 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 3032537

Group type: EXPERIMENTAL
Intervention: Guar administration (5-g minitablets, three times per day with main meals for 8 weeks)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Guar administration
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31522924

Group type: EXPERIMENTAL
Intervention: Smartphone application (app) for reporting symptoms, used weekly or sooner if symptoms worsened
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Smartphone application (app) for reporting symptoms
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 60
Study: 31337168

Group type: EXPERIMENTAL
Intervention: Interfascial injection (IF Group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Perivascular injection with nerve stimulation (PV Group)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Comparison of IF Group and PV Group
Number of subjects: 56
Study: 28033130

Group type: EXPERIMENTAL
Intervention: Ergocalciferol
Number of subjects: 84

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study: 27337795

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS delivered to the left dorsolateral prefrontal cortex, 2 times daily for 10 days
Number of subjects: 70

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: 10 Hz rTMS
Number of subjects: 70
Study: 23819344

Group type: EXPERIMENTAL
Intervention: Fixed-dose perindopril and amlodipine combination
Number of subjects: 82
Study: 21976185

Group type: EXPERIMENTAL
Intervention: Hi‐Ox80 mask
Number of subjects: 6

Group type: COMPARATOR
Intervention: Heliox21 mask
Number of subjects: 6

Group type: COMPARATOR
Intervention: Standard high-concentration face mask
Number of subjects: 6
Study: 18379751

Group type: EXPERIMENTAL
Intervention: Fast-track treatment
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 50
Study: 16564862

Group type: EXPERIMENTAL
Intervention: 4 F sphincterotome
Number of subjects: 107

Group type: COMPARATOR
Intervention: 5 F sphincterotome
Number of subjects: 107
Study: 12672842

Group type: EXPERIMENTAL
Intervention: Five-pin external fixator
Number of subjects: 50

Group type: COMPARATOR
Intervention: Four-pin external fixator
Number of subjects: 50
Study: 10765092

Group type: EXPERIMENTAL
Intervention: Orchiectomy combined with adjuvant mitomycin C (MMC; 15 mg/m(2) i.v. q 6 weeks)
Number of subjects: 189

Group type: COMPARATOR
Intervention: Orchiectomy alone (ORCH)
Number of subjects: 189
Study: 8889684

Group type: EXPERIMENTAL
Intervention: Ethanol (0, 0.28, 0.52 g/kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cocaine (4, 48, 96 mg/70 kg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Marijuana (0, 1.75, 3.55% THC)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Drug Recognition Examiner (DRE) assessments
Number of subjects: 18
Study: 1893348

Group type: EXPERIMENTAL
Intervention: Intrapleural doxorubicin plus LC9018 (38 patients)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Doxorubicin alone (38 patients)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Intrapleural doxorubicin plus LC9018
Number of subjects: 76
Study: 6550147

Group type: EXPERIMENTAL
Intervention: Prototype health education curriculum
Number of subjects: 60

Group type: COMPARATOR
Intervention: Traditional health screening program
Number of subjects: 60
Study: 31050707

Group type: EXPERIMENTAL
Intervention: pembrolizumab (200 mg every 3 weeks)
Number of subjects: 542

Group type: COMPARATOR
Intervention: chemotherapy (paclitaxel 175 mg/m2, docetaxel 75 mg/m2, or vinflunine 320 mg/m2, all every 3 weeks)
Number of subjects: 542

Group type: EXPERIMENTAL
Intervention: pembrolizumab
Number of subjects: 542
Study: 29139592

Group type: EXPERIMENTAL
Intervention: 1 g single dose systemic acetaminophen
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Oral opioid consumption
Number of subjects: 70
Study: 25596179

Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate (TDF, 300 mg/day) monotherapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate (TDF, 300 mg/day) and entecavir (ETV, 1 mg/day) combination therapy
Number of subjects: 90
Study: 24449105

Group type: EXPERIMENTAL
Intervention: Centre-based exercise group (n = 10)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Home-based exercise group (n = 8)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (n = 9)
Number of subjects: 27
Study: 22039171

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) delivered orally (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) delivered to proximal small bowel (PSB) (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) delivered to distal small bowel (DSB) (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) delivered to ascending colon (AC) (50 mg)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 18
Study: 18997106

Group type: EXPERIMENTAL
Intervention: Agaricus sylvaticus (30 mg/kg/day)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56